These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10197889)

  • 21. Early enteral supplementation with key pharmaconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial.
    Beale RJ; Sherry T; Lei K; Campbell-Stephen L; McCook J; Smith J; Venetz W; Alteheld B; Stehle P; Schneider H
    Crit Care Med; 2008 Jan; 36(1):131-44. PubMed ID: 18007263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Megavitamin therapy.
    Hodges RE
    Prim Care; 1982 Sep; 9(3):605-19. PubMed ID: 6924387
    [No Abstract]   [Full Text] [Related]  

  • 23. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
    Akhondzadeh S; Tabatabaee M; Amini H; Ahmadi Abhari SA; Abbasi SH; Behnam B
    Schizophr Res; 2007 Feb; 90(1-3):179-85. PubMed ID: 17208413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol.
    Bošković M; Vovk T; Koprivšek J; Plesničar BK; Grabnar I
    Nutr Neurosci; 2016 May; 19(4):156-61. PubMed ID: 25056532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens.
    Fransen M; Agaliotis M; Nairn L; Votrubec M; Bridgett L; Su S; Jan S; March L; Edmonds J; Norton R; Woodward M; Day R;
    Ann Rheum Dis; 2015 May; 74(5):851-8. PubMed ID: 24395557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial.
    Behdani F; Hebrani P; Rezaei Ardani A; Rafee E
    Arch Iran Med; 2011 Jul; 14(4):270-5. PubMed ID: 21726104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Megavitamins for minimal brain dysfunction. A potentially dangerous therapy.
    Shaywitz BA; Siegel NJ; Pearson HA
    JAMA; 1977 Oct; 238(16):1749-50. PubMed ID: 578271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
    Fleischhacker WW; Heikkinen ME; Olié JP; Landsberg W; Dewaele P; McQuade RD; Loze JY; Hennicken D; Kerselaers W
    Int J Neuropsychopharmacol; 2010 Sep; 13(8):1115-25. PubMed ID: 20459883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.
    Buchanan RW; Kirkpatrick B; Bryant N; Ball P; Breier A
    Am J Psychiatry; 1996 Dec; 153(12):1625-7. PubMed ID: 8942462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
    Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
    J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
    Chen CH; Huang MC; Kao CF; Lin SK; Kuo PH; Chiu CC; Lu ML
    J Clin Psychiatry; 2013 May; 74(5):e424-30. PubMed ID: 23759461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical trial of adjunctive oestrogen treatment in women with schizophrenia.
    Kulkarni J; Riedel A; de Castella AR; Fitzgerald PB; Rolfe TJ; Taffe J; Burger H
    Arch Womens Ment Health; 2002 Nov; 5(3):99-104. PubMed ID: 12510212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind trial of adjunctive allopurinol for schizophrenia.
    Dickerson FB; Stallings CR; Origoni AE; Sullens A; Khushalani S; Sandson N; Yolken RH
    Schizophr Res; 2009 Apr; 109(1-3):66-9. PubMed ID: 19195842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of dietary supplements on depressive symptoms in older patients: a randomised double-blind placebo-controlled trial.
    Gariballa S; Forster S
    Clin Nutr; 2007 Oct; 26(5):545-51. PubMed ID: 17662509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.
    Freudenreich O; Henderson DC; Walsh JP; Culhane MA; Goff DC
    Schizophr Res; 2007 May; 92(1-3):90-4. PubMed ID: 17321111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.